Search results
Results From The WOW.Com Content Network
Eplerenone, sold under the brand name Inspra, is an aldosterone antagonist type of potassium-sparing diuretic that is used to treat chronic heart failure and high blood pressure, particularly for people with resistant hypertension due to elevated aldosterone.
There’s no best time to take metformin for weight loss or type 2 diabetes (or any other condition). But taking it at the same time each day can help you stay consistent and avoid missing or ...
Eplerenone is a newer drug that was developed as a spironolactone analog with reduced adverse effects. In addition to the y-lactone ring and the substituent on C-7, eplerenone has a 9α,11α-epoxy group. This group is believed to be the reason why eplerenone has a 20-40-fold lower affinity for the mineralocorticoid receptor than spironolactone. [7]
[24] [26] It has been determined that 7α-TMS accounts for around 80% of the potassium-sparing effect of spironolactone [1] [2] [3] while canrenone accounts for the remaining approximately 10 to 25%. [4] Accordingly, 7α-TMS occurs at higher circulating concentrations than does canrenone in addition to having a higher relative affinity for the ...
Potassium-sparing diuretics or antikaliuretics [1] refer to drugs that cause diuresis without causing potassium loss in the urine. [2] They are typically used as an adjunct in management of hypertension, cirrhosis, and congestive heart failure. [3] The steroidal aldosterone antagonists can also be used for treatment of primary hyperaldosteronism.
Eplerenone, a steroidal antimineralocorticoid of the spirolactone group; Estriol triacetate, an estrogen medication and an estrogen ester
morning: ante meridiem: nocte every night Omne Nocte a.s., as, AS left ear auris sinistra a.u., au, AU both ears together or each ear aures unitas or auris uterque b.d.s, bds, BDS 2 times a day bis die sumendum b.i.d., bid, BID twice a day / twice daily bis in die gtt., gtts drop(s) gutta(e) h., h hour: hora: qhs, h.s., hs at bedtime or half ...
Two studies of canrenone in people with heart failure have shown a mortality benefit compared to placebo. In the evaluation which studied people with chronic heart failure (CHF), people that were treated with canrenone displayed a lower number of deaths compared to the placebo group, indicating a death and morbidity benefit of the medication.